These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35676232)

  • 21. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
    Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
    Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein.
    Zhang J; Tang W; Gao H; Lavine CL; Shi W; Peng H; Zhu H; Anand K; Kosikova M; Kwon HJ; Tong P; Gautam A; Rits-Volloch S; Wang S; Mayer ML; Wesemann DR; Seaman MS; Lu J; Xiao T; Xie H; Chen B
    Nat Struct Mol Biol; 2023 Jul; 30(7):980-990. PubMed ID: 37430064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ablation of CD8
    Swaminathan S; Lineburg KE; Panikkar A; Raju J; Murdolo LD; Szeto C; Crooks P; Le Texier L; Rehan S; Dewar-Oldis MJ; Barnard PJ; Ambalathingal GR; Neller MA; Short KR; Gras S; Khanna R; Smith C
    Nat Commun; 2022 Oct; 13(1):6387. PubMed ID: 36302758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of a second SARS-CoV-2 variant with a tremendous genetic leap from its ancestors.
    Colson P; La Scola B; Beye M; Delerce J; Raoult D; Fantini J
    J Med Virol; 2023 Oct; 95(10):e29124. PubMed ID: 37811585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites.
    Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant.
    Müller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Söderdahl G; Smith CIE; Loré K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren HG; Österborg A; Sette A; Grifoni A; Aleman S; Buggert M
    Cell Host Microbe; 2024 Feb; 32(2):156-161.e3. PubMed ID: 38211584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant.
    Qu P; Evans JP; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Nov; 30(11):1518-1526.e4. PubMed ID: 36240764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus.
    Kibria KMK; Faruque MO; Islam MSB; Ullah H; Mahmud S; Miah M; Saleh AA
    Appl Microbiol Biotechnol; 2022 Jun; 106(11):4091-4114. PubMed ID: 35612630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1.
    Muik A; Quandt J; Lui BG; Bacher M; Lutz S; Grünenthal M; Toker A; Grosser J; Ozhelvaci O; Blokhina O; Shpyro S; Vogler I; Salisch N; Türeci Ö; Sahin U
    Cell Rep; 2024 Aug; 43(8):114567. PubMed ID: 39097927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron.
    Wiegand T; Nemudryi A; Nemudraia A; McVey A; Little A; Taylor DN; Walk ST; Wiedenheft B
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant.
    Choi SJ; Kim DU; Noh JY; Kim S; Park SH; Jeong HW; Shin EC
    Cell Mol Immunol; 2022 Mar; 19(3):447-448. PubMed ID: 35043006
    [No Abstract]   [Full Text] [Related]  

  • 36. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
    Kimura I; Yamasoba D; Nasser H; Ito H; Zahradnik J; Wu J; Fujita S; Uriu K; Sasaki J; Tamura T; Suzuki R; Deguchi S; Plianchaisuk A; Yoshimatsu K; Kazuma Y; Mitoma S; Schreiber G; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Takaori-Kondo A; ; Ito J; Shirakawa K; Takayama K; Irie T; Hashiguchi T; Nakagawa S; Fukuhara T; Saito A; Ikeda T; Sato K
    J Virol; 2023 Oct; 97(10):e0101123. PubMed ID: 37796123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.
    Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.